/
STOK
$31.31-$1.66 (-5.03%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.1B
65M shares
52-week range
$15.50 – $40.22
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$6.69
Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
www.stoketherapeutics.com- Employees
- 170
- IPO / List date
- Jun 19, 2019
- HQ
- BEDFORD, MA
Held by traders on TradeandTell
No one on the platform currently holds STOK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 178,300 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded STOK yet.
